Physician profile
Rahil Rafeedheen
NPI 1649526716
$30,530.11
in general payments reported to CMS, 2019-2025
34 companies · $16K in 2025
The $16K reported for 2025 was more than what 91% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,258 · 2020: $347 · 2021: $649 · 2022: $1,611 · 2023: $681 · 2024: $5,065 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,300 · Travel and Lodging: $4,253 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $4,100 · Food and Beverage: $4,012 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,300.00 |
| Travel and Lodging | $4,252.75 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $4,100.00 |
| Food and Beverage | $4,011.77 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $22,490.77 | 2019-2025 | Dragonfly Opstar, Ultreon, Optis |
| Edwards Lifesciences Corporation | $1,633.81 | 2019-2025 | Evoque, Sapien 3 Ultra Resilia, Pascal |
| Medtronic, INC. | $1,304.26 | 2021-2025 | Corevalve Evolut R |
| Medtronic Vascular, INC. | $1,009.07 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $615.05 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $612.54 | 2019-2025 | Avvigo Guidance System, Ekosonic, Eluvia |
| Abiomed | $484.97 | 2019-2025 | |
| Pfizer INC. | $291.51 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $289.75 | 2021-2025 | |
| Inari Medical, INC. | $173.35 | 2022-2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $172.01 | 2020-2025 | Lifevest |
| Bard Peripheral Vascular, INC. | $167.74 | 2019-2020 | |
| Shockwave Medical, INC | $166.94 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Amgen INC. | $146.20 | 2019-2025 | Repatha, Repatha |
| Cardiovascular Systems INC. | $130.05 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $122.47 | 2025 | Flowtriever |
| Genzyme Corporation | $90.32 | 2019 | |
| Chiesi USA, INC. | $84.29 | 2021-2025 | Juxtapid |
| Actelion Pharmaceuticals US, INC. | $66.73 | 2019-2022 | |
| Novo Nordisk INC | $65.72 | 2020-2024 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $56.52 | 2019-2020 | |
| Terumo Medical Corporation | $54.72 | 2020-2023 | Angio-Seal |
| W. L. Gore & Associates, INC. | $52.40 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $50.36 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.77 | 2023-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $25.88 | 2022-2023 | Verquvo |
| Merge Healthcare Incorporated | $22.86 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $19.13 | 2023 | Camzyos |
| Alnylam Pharmaceuticals INC. | $17.03 | 2024 | Onpattro |
| Livanova USA, INC. | $16.06 | 2023 | Lifesparc |
| Esperion Therapeutics, INC. | $15.14 | 2021 | |
| Kiniksa Pharmaceuticals, Ltd. | $14.79 | 2022 | |
| Braemar Manufacturing, LLC | $14.12 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.78 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rahil Rafeedheen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.